Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Reduce Inflammation? What C-Reactive Protein Can Tell Us

Semaglutide lowered C-reactive protein in randomized studies. Heart failure and inflammatory bowel disease studies measured different outcomes.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
C-reactive protein change−40.90Percentage-point difference versus placeboReview of nine randomized trials

Randomized trials found that injected semaglutide lowered C-reactive protein (CRP) in adults with overweight or obesity and without diabetes. The review’s comparison of weight and CRP changes uses percentage changes from two different starting values. It estimated a 40.90 percentage-point greater reduction in CRP versus placebo (95% CI 35.42–46.37 points greater). The review included nine trials with 6,239 participants in total.[2]

What the heart failure trials measured

The VA study of GLP-1 health outcomes examined a much broader set of outcomes in medical records. These randomized trials examined a narrower group and measured changes in an inflammation marker.

A separate analysis pooled two randomized STEP-HFpEF trials with 1,145 participants in the analysis set. Participants had obesity-related heart failure with preserved ejection fraction. Semaglutide lowered CRP more than placebo over 52 weeks. The analysis found no statistically clear differences in the treatment’s effects on symptoms, physical limitations, or six-minute walk distance across baseline CRP groups.[1]

What researchers found in inflammatory bowel disease

A matched study of people with inflammatory bowel disease treated with tirzepatide compared 3,042 people per group. The tirzepatide group had lower adjusted hazard of receiving intravenous steroids than the comparison group prescribed GLP-1 agonists (adjusted hazard ratio 0.81, 95% CI 0.68–0.94).[3]

Hospitalization, emergency visits, and intestinal surgery showed no statistically clear differences. The record-based study cannot establish that tirzepatide treats inflammatory bowel disease.[3]

Frequently asked

Do GLP-1 drugs reduce inflammation?
Randomized trials show that semaglutide lowers C-reactive protein, a blood marker of inflammation. This does not establish a benefit for every medication in the class or every inflammatory disease.
Can weight loss explain the change in C-reactive protein?
A heart failure analysis did not detect a statistically clear difference in the effect on C-reactive protein across weight-loss groups. That analysis could not establish how much of the change was caused by weight loss.

Sources

  1. [1] Verma S, et al. (2024). Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program Journal of the American College of Cardiology. PMID 39217564
  2. [2] Milluzzo A, et al. (2026). Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis International Journal of Obesity. PMID 42668312
  3. [3] Patel KS, et al. (2026). Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study Intestinal Research. PMID 42717572

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence